GLP-3/RT: The Next-Generation Triple Receptor Agonist
An overview of GLP-3/RT, the novel GIP/GLP-1/glucagon triple agonist peptide generating significant interest in metabolic research across Canada and globally.
- GLP-3/RT is a synthetic peptide that simultaneously activates three hormone receptors — GIP, GLP-1, and glucagon — distinguishing it from dual agonists such as GLP-2/Tirz, which target GIP and GLP-1 only.
- Each receptor contributes a distinct studied effect: GIP with glucose-dependent insulin secretion, GLP-1 with appetite and glucose signalling, and glucagon with hepatic glucose output and energy expenditure.
- Published Phase 2 clinical-trial data reported substantial body-weight reductions in study participants over 24–48 weeks, with preclinical work also exploring NASH, cardiovascular markers, and glycaemic control.
- Canadian researchers in metabolic disease, obesity biology, and endocrinology use GLP-3/RT as a tool for studying incretin physiology and energy homeostasis.
- Supplied strictly for in vitro and laboratory research use only — not approved by Health Canada for therapeutic application.
What Is GLP-3/RT?
GLP-3/RT is a synthetic peptide that simultaneously activates three distinct hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. This triple-agonist mechanism distinguishes it from earlier compounds in metabolic research and has made it a subject of intense scientific interest.
Unlike dual agonists such as GLP-2/Tirz, which target GIP and GLP-1 only, GLP-3/RT adds glucagon receptor activation — a pathway associated with increased energy expenditure and hepatic fat reduction. This additional mechanism is thought to create a more comprehensive effect on metabolic regulation in preclinical models.
Mechanism of Action
The three receptors targeted by GLP-3/RT are expressed throughout the body, including in the pancreas, brain, liver, and gastrointestinal tract.
**GIP receptor activation** has been associated with enhanced insulin secretion in a glucose-dependent manner. Research also suggests GIP signalling may play a role in adipose tissue regulation and bone metabolism.
**GLP-1 receptor activation** is well-established in metabolic research. GLP-1 agonism has been studied for its effects on insulin secretion, glucagon suppression, gastric emptying, and central appetite signalling pathways.
**Glucagon receptor activation**, the unique addition in GLP-3/RT, is associated with increased hepatic glucose output, enhanced fatty acid oxidation, and elevated energy expenditure. While glucagon itself can raise blood glucose, its effects within the context of combined GIP and GLP-1 agonism appear to be modulated in preclinical studies.
Research Findings
Early phase clinical trials of GLP-3/RT have generated considerable interest in the research community. Published data from Phase 2 studies demonstrated substantial reductions in body weight among participants over 24 to 48 weeks of treatment, with effects appearing to exceed those observed with earlier generation incretin therapies.
Preclinical models have also explored GLP-3/RT's potential in areas beyond weight regulation, including non-alcoholic steatohepatitis (NASH), cardiovascular risk markers, and glycaemic control. Research is ongoing across these areas.
Research Applications in Canada
Canadian researchers studying metabolic disease, obesity biology, and endocrinology have shown growing interest in GIP/GLP-1/glucagon triple agonist compounds. As the mechanism of GLP-3/RT becomes better understood, its utility as a research tool for exploring incretin physiology and energy homeostasis continues to expand.
Popular Peptides supplies research-grade GLP-3/RT to Canadian researchers with independent third-party testing and a Certificate of Analysis provided with every order.
Important Notice
All compounds supplied by Popular Peptides are strictly for in vitro and laboratory research use only. They are not intended for human or veterinary use, and are not approved by Health Canada for therapeutic application. Researchers should comply with all applicable institutional and regulatory guidelines.
What to order
Compounds referenced in this guide:
- —**GLP-3/RT**
Popular Peptides ships from Vancouver, BC — typically 2 to 5 business days, tracked and insured, with no customs clearance and no border seizure risk. Every batch is third-party tested (HPLC for purity, LC-MS for identity) and its certificate of analysis is retrievable by lot number. Priced in Canadian dollars, free shipping over $300 CAD.
Browse every published lab result before you order, or check the reference library for molecular data on each compound.
Frequently asked questions
What makes GLP-3/RT a triple agonist?
It engages three receptors — GIP, GLP-1 and glucagon — where semaglutide engages one and tirzepatide two. The glucagon arm is the distinguishing element, associated with increased energy expenditure and hepatic fat mobilisation.
Is GLP-3/RT approved for therapeutic use?
No. Retatrutide is an investigational compound not approved by Health Canada, the FDA or the EMA. GLP-3/RT is supplied strictly for in vitro laboratory research.
What purity is your GLP-3/RT?
Greater than 99%, confirmed by HPLC for purity and LC-MS for identity by an independent third-party laboratory. The certificate for your batch is retrievable by lot number on our verification page.
Every batch we sell is independently third-party tested, with the full Certificate of Analysis published and checkable by lot number.